{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:01:15Z","timestamp":1792425675717,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006356","name":"Syddansk Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Optic neuritis (ON) is a common inflammatory optic neuropathy, which often occurs in neuromyelitis optica spectrum disease (NMOSD). An experimental model of NMOSD-ON may provide insight into disease mechanisms.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To examine the pathogenicity of autoantibodies targeting the astrocyte water channel aquaporin-4 [aquaporin-4 (AQP4)-immunoglobulin G (AQP4-IgG)] in the optic nerve.<\/jats:p><jats:p><jats:bold>Materials and Methods:<\/jats:bold> Purified IgG from an AQP4-IgG-positive NMOSD-ON patient was together with human complement (C) given to wild-type (WT) and type I interferon (IFN) receptor-deficient mice (IFNAR1-KO) as two consecutive intrathecal injections into cerebrospinal fluid <jats:italic>via<\/jats:italic> cisterna magna. The optic nerves were isolated, embedded in paraffin, cut for histological examination, and scored semi-quantitatively in a blinded fashion. In addition, optic nerves were processed to determine selected gene expression by quantitative real-time PCR.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Intrathecal injection of AQP4-IgG+C induced astrocyte pathology in the optic nerve with loss of staining for AQP4 and glial fibrillary acidic protein (GFAP), deposition of C, and demyelination, as well as upregulation of gene expression for interferon regulatory factor-7 (IRF7) and CXCL10. Such pathology was not seen in IFNAR1-KO mice nor in control mice.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We describe induction of ON in an animal model for NMOSD and show a requirement for type I IFN signaling in the disease process.<\/jats:p>","DOI":"10.3389\/fneur.2021.703249","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T16:30:08Z","timestamp":1627057808000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["An Experimental Model of Neuromyelitis Optica Spectrum Disorder\u2013Optic Neuritis: Insights Into Disease Mechanisms"],"prefix":"10.3389","volume":"12","author":[{"given":"Sofie Forsberg","family":"Soerensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wirenfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wlodarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene Thorsen","family":"Moerch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Khorooshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina S.","family":"Arengoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeren Thue","family":"Lillevang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1474-4422(05)00992-0","article-title":"The neuro-ophthalmology of multiple sclerosis","volume":"4","author":"Frohman","year":"2005","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology."},{"key":"B3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1474-4422(17)30278-8","article-title":"Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis","volume":"16","author":"Petzold","year":"2017","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e66151","DOI":"10.1371\/journal.pone.0066151","article-title":"Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis","volume":"8","author":"Schneider","year":"2013","journal-title":"PLoS ONE."},{"key":"B5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult Scler."},{"key":"B6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain."},{"key":"B11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1742-2094-11-16","article-title":"Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G","volume":"11","author":"Asavapanumas","year":"2014","journal-title":"J Neuroinflammation."},{"key":"B12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/2051-5960-2-48","article-title":"Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury","volume":"2","author":"Asavapanumas","year":"2014","journal-title":"Acta Neuropathol Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jneuroim.2012.09.010","article-title":"Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid","volume":"254","author":"Asgari","year":"2013","journal-title":"J Neuroimmunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/acn3.221","article-title":"Cerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier","volume":"2","author":"Asgari","year":"2015","journal-title":"Ann Clin Transl Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/glia.23938","article-title":"Type I interferon-activated microglia are critical for neuromyelitis optica pathology","volume":"69","author":"Wlodarczyk","year":"2020","journal-title":"Glia."},{"key":"B17","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.expneurol.2013.02.005","article-title":"Neuromyelitis optica-like pathology is dependent on type I interferon response","volume":"247","author":"Khorooshi","year":"2013","journal-title":"Exp Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-1-59259-345-3_21","article-title":"Cytokine gene delivery into the central nervous system using intrathecally injected non replicative viral vectors","volume":"215","author":"Furlan","year":"2003","journal-title":"Methods Mol Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.4049\/jimmunol.178.12.8175","article-title":"IFN-\u03b3-induced chemokines synergize with pertussis toxin to promote T cell entry to the central nervous system","volume":"178","author":"Millward","year":"2007","journal-title":"J Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.immuni.2008.03.011","article-title":"Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system","volume":"28","author":"Prinz","year":"2008","journal-title":"Immunity."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"Population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1352458511417480","article-title":"PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica","volume":"18","author":"Asgari","year":"2012","journal-title":"Mult Scler."},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1600-0404.2010.01416.x","article-title":"Neuromyelitis optica (NMO) \u2013 an autoimmune disease of the central nervous system (CNS)","volume":"123","author":"Asgari","year":"2011","journal-title":"Acta Neurol Scand."},{"key":"B25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.preteyeres.2013.03.001","article-title":"Optic neuritis in neuromyelitis optica","volume":"36","author":"Levin","year":"2013","journal-title":"Prog Retin Eye Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1155\/2006\/586306","article-title":"NMO-IgG: a specific biomarker for neuromyelitis optica","volume":"22","author":"Weinshenker","year":"2006","journal-title":"Dis Markers."},{"key":"B27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-015-0259-2","article-title":"Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody","volume":"3","author":"Kurosawa","year":"2015","journal-title":"Acta Neuropathol Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/bpa.12098","article-title":"Experimental models of neuromyelitis optica","volume":"24","author":"Bradl","year":"2014","journal-title":"Brain Pathol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1172\/JCI134816","article-title":"Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest."},{"key":"B31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica","author":"Melamed","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"713519","DOI":"10.1155\/2013\/713519","article-title":"Interferon alpha association with neuromyelitis optica","volume":"2013","author":"Asgari","year":"2013","journal-title":"Clin Dev Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1474-4422(19)30445-4","article-title":"Study group. Neuromyelitis optica in patients with increased interferon alpha concentrations","volume":"19","author":"Williams","year":"2020","journal-title":"Lancet Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jnr.22181","article-title":"Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis","volume":"88","author":"Wang","year":"2010","journal-title":"J Neurosci Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1212\/WNL.0000000000001520","article-title":"Challenges and opportunities in designing clinical trials for neuromyelitis optica","volume":"84","author":"Weinshenker","year":"2015","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectr.um disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin Proc."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.703249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T16:30:11Z","timestamp":1627057811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.703249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":39,"alternative-id":["10.3389\/fneur.2021.703249"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.703249","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"article-number":"703249"}}